 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Dendreon Corporation
 |
Dendreon Corporation |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
Gene Schemes
Jul 16 2001 12:00 AM PDT
PROFILE |
 |
Dendreon isn't really branching out that much; the company is sticking to what it knows -- cancer research based on its cell separation technologies. The company is developing therapeutic vaccines that goose the body's immune system to help it fight cancer. Its lead product candidate is Provenge, a prostate cancer vaccine. Dendreon is also developing vaccines to treat breast, colorectal, lung, ovarian, and uterine cancers, among others. The company has alliances with Japan's Kirin Brewery and a unit of Johnson & Johnson. Healthcare Ventures and Paul Allen's Vulcan Northwest each own about 15% of Dendreon. CEO Chris Henney, who also co-founded Immunex and Icos, founded Dendreon in 1992 as Activated Cell Therapy.
COMPETITION |
 |
Biomira Inc. (BIOM)
Cell Genesys, Inc. (CEGE)
Corixa Corporation (CRXA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 6.50
1-Yr. Sales Growth: 75.7%
Employees: 99
Revenue per employee: $65,656.57
KEY PEOPLE |
 |
Christopher S. Henney
CEO
Martin A. Simonetti
CFO
CONTACT INFO |
 |
3005 First Ave.
Seattle, WA 98121
US
Phone: 206-256-4545
Fax: 206-256-0571
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |